Bacil Pharma Intrinsic Value
Bacil Pharma (BACPHAR) median intrinsic value is ₹16.37 from 7 valuation models (range ₹16–₹36), vs current price ₹54.56 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Also explore BACPHAR share price history to track price trends across different timeframes.
BACPHAR Valuation Methods Summary — DCF, Graham Number & P/E
Bacil Pharma intrinsic value across 7 models vs current price ₹54.56 — upside/downside and value range per method. For current market price and key ratios, visit Bacil Pharma share price chart.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹16.37 | ₹13.10 - ₹19.64 | -70.0% | EPS: ₹0.60, Sector P/E: 22x |
| Book Value Method | asset | ₹35.71 | ₹32.14 - ₹39.28 | -34.5% | Book Value/Share: ₹17.86, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹16.37 | ₹14.73 - ₹18.01 | -70.0% | Revenue/Share: ₹0.71, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹21.82 | ₹19.64 - ₹24.00 | -60.0% | EBITDA: ₹1.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹16.37 | ₹14.73 - ₹18.01 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹16.37 | ₹14.73 - ₹18.01 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹16.37 | ₹14.73 - ₹18.01 | -70.0% | EPS: ₹0.60, BVPS: ₹17.86 |
BACPHAR Intrinsic Value vs Market Price — All Valuation Models
Bacil Pharma fair value range ₹16–₹36 vs current market price ₹54.56 across 7 valuation models. Browse BACPHAR annual financials for revenue, profit, balance sheet and cash flow data.
BACPHAR Intrinsic Value Analysis — Undervalued or Overvalued?
Bacil Pharma median intrinsic value ₹16.37, current price ₹54.56 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of BACPHAR?
Based on our comprehensive analysis using 7 different valuation methods, the estimated intrinsic value of Bacil Pharma (BACPHAR) is ₹16.37 (median value). With the current market price of ₹54.56, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹16.37 to ₹35.71, indicating ₹16.37 - ₹35.71.
Is BACPHAR undervalued or overvalued?
Based on our multi-method analysis, Bacil Pharma (BACPHAR) appears to be trading above calculated value by approximately 70.0%.
BACPHAR Financial Health — Key Ratios vs Industry Benchmarks
Bacil Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 4.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Asset Turnover Ratio | 0.04x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
BACPHAR Cash Flow Quality — Operating & Free Cash Flow
Bacil Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-4 Cr | ₹-4 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |